1
|
Ballul T, Sabato V, Bulai Livideanu C, Neuraz A, Lemal R, Tournilhac O, Terriou L, Launay D, Bouillet L, Gourguechon C, Damaj G, Durupt S, Frenzel L, Bouktit H, Gousseff M, Le Mouel E, Barète S, Hermine O, Lortholary O, Rossignol J. Caractérisation d’une nouvelle entité de maladie mastocytaire primaire associée à l’ostéoporose précoce et à l’anaphylaxie idiopathique: accumulation mastocytaire médullaire avec retentissement clinique (MMRC). Étude internationale du CEREMAST. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.10.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
2
|
van Gelder M, Tournilhac O, Te Raa D, Visser HPJ. Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL. Ann Oncol 2021; 32:1442-1443. [PMID: 34428511 DOI: 10.1016/j.annonc.2021.08.1990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Revised: 08/02/2021] [Accepted: 08/13/2021] [Indexed: 10/20/2022] Open
Affiliation(s)
- M van Gelder
- Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands.
| | - O Tournilhac
- Service for Cell Therapy and Clinic for Hematology, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France
| | - D Te Raa
- Department of Internal Medicine, Gelderse Vallei Hospital, Ede, the Netherlands
| | - H P J Visser
- Northwest Oncology Center, Northwest Hospital Group, Alkmaar, the Netherlands
| |
Collapse
|
3
|
Sibon D, Bisig B, Bonnet C, Bachy E, Cavalieri D, Fataccioli V, Drieux F, Bruneau J, Lemonnier F, Bossard C, Bouabdallah K, Parrens M, Damaj G, Tournilhac O, Jais JP, Gaulard P, de Leval L. IMPACT OF DUSP22 REARRANGEMENT ON THE PROGNOSIS OF SYSTEMIC ALK‐NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: A LYSA AND TENOMIC STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.137_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- D Sibon
- Necker University Hospital, Hematology Paris France
| | - B Bisig
- Lausanne University Hospital, Pathology Lausanne Switzerland
| | - C Bonnet
- Liège University Hospital, Clinical Hematology Unit Liège Belgium
| | - E Bachy
- Lyon‐Sud University Hospital, Hematology Pierre‐Bénite France
| | - D Cavalieri
- Clermont‐Ferrand University Hospital, Hematology Clermont‐Ferrand France
| | - V Fataccioli
- Mondor University Hospital, Pathology Créteil France
| | - F Drieux
- Henri Becquerel Cancer Center, Pathology Rouen France
| | - J Bruneau
- Necker University Hospital, Pathology Paris France
| | - F Lemonnier
- Mondor University Hospital, Hematology Créteil France
| | - C Bossard
- Nantes University Hospital, Pathology Nantes France
| | - K Bouabdallah
- Haut‐Lévêque University Hospital, Hematology Bordeaux France
| | - M Parrens
- Haut‐Lévêque University Hospital, Pathology Bordeaux France
| | - G Damaj
- Caen University Hospital, Hematology Caen France
| | - O Tournilhac
- Clermont‐Ferrand University Hospital, Hematology Clermont‐Ferrand France
| | - J. P Jais
- Necker University Hospital, Statistics Paris France
| | - P Gaulard
- Mondor University Hospital, Pathology Créteil France
| | - L de Leval
- Lausanne University Hospital, Pathology Lausanne Switzerland
| |
Collapse
|
4
|
Cavalieri D, Tournilhac O, Missiglia E, Bonnet C, Ledoux‐Pilon A, Bisig B, Cairoli A, Poullot E, Fataccioli V, Parrens M, Copin MC, Gutierrez FL, Xerri L, Bossard C, Wind R, Drieux F, Lhomme F, Daniel A, Clément‐Filliatre L, Lemmonier F, Morel P, Noël R, Brotelle T, Glaisner S, Sibon D, Yamani A, Bologna S, Queru K, Damaj G, Letailleur V, Villemagne B, Fleck E, Dupont E, Tchernonog E, Monjanel H, Wilde V, Vallois D, Gaulard P, Leval L. MONOMORPHIC EPITHELIOTROPIC INTESTINAL T‐CELL LYMPHOMA (MEITL): CLINICO‐PATHOLOGICAL ANALYSIS OF A MULTICENTER EUROPEAN COHORT. Hematol Oncol 2021. [DOI: 10.1002/hon.44_2879] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
5
|
Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, Lancesseur C, Le Bras F, Willems E, Tchernonog E, Chalopin T, Delarue R, Gressin R, Chauchet A, Gyan E, Cartron G, Bonnet C, Haioun C, Damaj G, Gaulard P, Fornecker L, Ghesquières H, Tournilhac O, Gomesda Silva M, Bouabdallah R, Salles G, Bachy E. Corrigendum to 'Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers': [Annals of Oncology Volume 29, Issue 3, March 2018, Pages 715-723]. Ann Oncol 2021; 32:945. [PMID: 33992519 DOI: 10.1016/j.annonc.2021.04.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Affiliation(s)
- G Fossard
- Hematology Department, CHU Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France; Claude Bernard Lyon 1 University, Lyon, France; Cancer Center of Lyon (CRCL), INSERM U1052 - CNRS UMR5286, Lyon, France
| | - F Broussais
- Hematology Department, CHU Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France
| | - I Coelho
- Hematology Department, Portuguese Institute of Oncology, Lisbon, Portugal
| | - S Bailly
- Hematology and Cell Therapy Department, Hôpital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand, France; Clermont Auvergne University, Clermont-Ferrand, France
| | | | - E Toussaint
- Hematology Department, CHU de Strasbourg, Strasbourg, France
| | | | - F Le Bras
- Hematology Department, CHU Henri Mondor, Creteil, France
| | - E Willems
- Hematology Department, CHU de Liège, Liège, Belgium
| | - E Tchernonog
- Hematology Department, CHU de Montpellier, Montpellier, France
| | - T Chalopin
- Hematology Department, CHU de Tours, Tours, France
| | - R Delarue
- Hematology Department, CHU Necker Enfants Malades, AP-HP, Paris, France
| | - R Gressin
- Hematology Department, CHU de Grenoble, Grenoble, France
| | - A Chauchet
- Hematology Department, CHU de Besançon, Besançon, France
| | - E Gyan
- Hematology Department, CHU de Tours, Tours, France
| | - G Cartron
- Hematology Department, CHU de Montpellier, Montpellier, France
| | - C Bonnet
- Hematology Department, CHU de Liège, Liège, Belgium
| | - C Haioun
- Hematology Department, CHU Henri Mondor, Creteil, France
| | - G Damaj
- Hematology Institute, CHU de Caen, Caen, France
| | - P Gaulard
- Hematology Department, CHU Henri Mondor, Creteil, France
| | - L Fornecker
- Hematology Department, CHU de Strasbourg, Strasbourg, France
| | - H Ghesquières
- Hematology Department, CHU Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France
| | - O Tournilhac
- Hematology and Cell Therapy Department, Hôpital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand, France; Clermont Auvergne University, Clermont-Ferrand, France
| | - M Gomesda Silva
- Hematology Department, Portuguese Institute of Oncology, Lisbon, Portugal
| | - R Bouabdallah
- Hematology Department, Institut Paoli Calmette, Marseille, France
| | - G Salles
- Hematology Department, CHU Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France; Claude Bernard Lyon 1 University, Lyon, France; Cancer Center of Lyon (CRCL), INSERM U1052 - CNRS UMR5286, Lyon, France
| | - E Bachy
- Hematology Department, CHU Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France; Claude Bernard Lyon 1 University, Lyon, France; Cancer Center of Lyon (CRCL), INSERM U1052 - CNRS UMR5286, Lyon, France.
| |
Collapse
|
6
|
Tournilhac O, Truemper L, Ziepert M, Bouabdallah K, Nickelsen M, Maury S, Reimer P, Jaccard A, Herr W, Wilhelm M, Cartron G, Wulf G, Sanhes L, Dreger P, Lamy T, Kroschinsky F, Lindemann H, Roussel M, Viardot A, Sibon D, Delmer A, De Leval L, Damaj G, Gisselbrecht C, Gaulard P, Rosenwald A, Friedrichs B, Altmann B, Schmitz N. FIRST-LINE THERAPY OF T-CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION - FINAL RESULTS OF THE AATT STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.64_2629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- O. Tournilhac
- Service d'Hematologie, EA7453 Chelter, CIC-1405; CHU de Clermont-Ferrand, Université Clermont Auvergne; Clermont-Ferrand France
| | - L. Truemper
- Hematology and Oncology; Georg August University Göttingen; Goettingen Germany
| | - M. Ziepert
- Statistics and Epidemology; Institute for Medical Informatics, Leipzig University; Leipzig Germany
| | - K. Bouabdallah
- Department of Haematology; University Hospital of Bordeaux; Bordeaux Pessac France
| | - M. Nickelsen
- Onkologie Lerchenfeld; Onkologie Lerchenfeld; Hamburg Germany
| | - S. Maury
- Université Paris-Est Créteil Val De Marne; AP-HP Hôpital Henri Mondor; Créteil France
| | - P. Reimer
- Hämatologie; Kliniken Essen-Sued; Essen Germany
| | - A. Jaccard
- Hématologie Clinique et Thérapie Cellulaire; CHU de Limoges - Hôpital Dupuytren; Limoges France
| | - W. Herr
- Department of Internal Medicine III; University Medical Center of the Johannes Gutenberg-University; Mainz Germany
| | - M. Wilhelm
- Med. Klinik 5; Klinikum Nuernberg; Nuernberg Germany
| | - G. Cartron
- Service d'Hématologie Clinique; CHU de Montpellier, UMR CNRS 5235; Montpellier France
| | - G. Wulf
- Hematology and Oncology; Georg August University Göttingen; Goettingen Germany
| | - L. Sanhes
- Hematology; Centre Hospitalier Saint Jean; Perpignan France
| | - P. Dreger
- Internal Medicine V; University of Heidelberg; Heidelberg Germany
| | - T. Lamy
- Rennes University Hospital; INSERM Research Unit 1236, Rennes University; Rennes France
| | - F. Kroschinsky
- Medical Department I; Dresden University Hospital; Dresden Germany
| | - H. Lindemann
- Hematology Oncology Clinic; Saint Josefs Hospital; Hagen Germany
| | - M. Roussel
- Service d'Hématologie; IUC Oncopole; Toulouse France
| | - A. Viardot
- Internal Medicine III; University Hospital Ulm; Ulm Germany
| | - D. Sibon
- Hematology; CHU Necker; Paris France
| | - A. Delmer
- Hematology; CHU Robert Debré; Reims France
| | - L. De Leval
- Pathologie Clinique; Institut Universitaire de Pathologie; Lausanne Switzerland
| | - G.L. Damaj
- Institut d'Hématologie; CHU de Caen; Caen France
| | | | - P. Gaulard
- Département de Pathologie; Groupe Hospitalier Henri Mondor; Créteil France
| | - A. Rosenwald
- Institute of Pathology; University of Wuerzburg; Wuerzburg Germany
| | - B. Friedrichs
- Hämatologie; Medizinische Klinik A Hämatologie UniversitätsklinikMünster; Münster Germany
| | - B. Altmann
- Statistics and Epidemology; Institute for Medical Informatics (IMISE); Leipzig Germany
| | - N. Schmitz
- Hämatologie; Medizinische Klinik A Hämatologie UniversitätsklinikMünster; Münster Germany
| |
Collapse
|
7
|
Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, Lancesseur C, Le Bras F, Willems E, Tchernonog E, Chalopin T, Delarue R, Gressin R, Chauchet A, Gyan E, Cartron G, Bonnet C, Haioun C, Damaj G, Gaulard P, Fornecker L, Ghesquières H, Tournilhac O, da Silva MG, Bouabdallah R, Salles G, Bachy E. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol 2018; 29:715-723. [DOI: 10.1093/annonc/mdx787] [Citation(s) in RCA: 69] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Zinzani P, Wagner-Johnston N, Miller C, Ardeshna K, Tertreault S, Assouline S, Mayer J, Passamonti F, Lunin S, Pettitt A, Nagy Z, Tournilhac O, Abou-Nassar K, Crump M, Jacobsen E, De Vos S, Youssoufian H, Porter J, Prado S, Flinn I. DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_57] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- P. Zinzani
- Institute of Hematology Serágnoli; University of Bologna; Bologna Italy
| | | | - C. Miller
- Cancer Institute; St. Agnes Hospital; Baltimore USA
| | - K. Ardeshna
- Cancer Center; University College London; London UK
| | - S. Tertreault
- Department of Hematology; Florida Cancer Specialists Tallahassee; Tallahassee USA
| | - S. Assouline
- Division of Hematology; Jewish General Hospital; Montreal Canada
| | - J. Mayer
- Interni hematologicka; Onkologicka klinika-FN Brno; Brno Czech Republic
| | - F. Passamonti
- Oncology; Ospedale Di Circolo e Fondazione Macchi U.O. Ematologia; Varese Italy
| | - S. Lunin
- Hematology/Oncology; Florida Cancer Specialist Sarasotta; Sarasotta USA
| | - A. Pettitt
- Department of Molecular and Clinical Cancer Medicine, North West Cancer Research Centre; University of Liverpool; Liverpool UK
| | - Z. Nagy
- Belgyogyaszati Klinika; Semmelweis Egyetem, I. sz; Budapest Hungary
| | - O. Tournilhac
- Service d'hématologie; CHU Estaing; Clermont-Ferrand France
| | - K. Abou-Nassar
- Hematology; Centre intégré de santé et de services sociaux de l'Outaouais; Gatineau Canada
| | - M. Crump
- Hematology; Princess Margaret Cancer Center; Toronto Canada
| | - E. Jacobsen
- Hematology and Oncology; Beth Israel Deaconess Medical Center; Boston USA
| | - S. De Vos
- Hematology and Oncology; Ronald Reagan UCLA Medical Center; Los Angeles USA
| | | | - J. Porter
- Clinical Development; Verastem Inc.; Needham USA
| | - S. Prado
- Clinical Development; Verastem Inc.; Needham USA
| | - I. Flinn
- Hematology and Oncology; Sarah Cannon Research Institute; Nashville USA
| |
Collapse
|
9
|
Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker L, Salles G, Tilly H, Lamy T, Gressin R, Hermine O. Rituximab maintenance after autologous stem-cell transplantation in patients with mantle cell lymphoma, final result of the LyMA trial conducted on behalf the LYSA group. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_74] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
| | - C. Thieblemont
- Hemato-Oncologie, APHP, Hôpital Saint-Louis; Paris France
| | - L. Oberic
- Hématologie, IUCT Oncopole; Toulouse France
| | - A. Moreau
- Hématologie, CHU De Nantes; Nantes France
| | | | | | - G. Damaj
- Hématologie, CHU Caen; Caen France
| | | | | | | | | | | | - C. Haioun
- hématologie, CHU Creteil; Creteil France
| | | | | | - O. Tournilhac
- Hématologie, CHU Clermont-Ferrand; Clermont-Ferrand France
| | - K. Le Dû
- Hématologie, Clinique Victor Hugo; Le Mans France
| | | | - G. Cartron
- hématologie, CHU Montpellier; Montpellier France
| | | | - G. Salles
- Hématologie, AP-HL Lyon; Lyon France
| | - H. Tilly
- hématologie, Centre Becquerel; Rouen France
| | - T. Lamy
- Hématologie, CHU Rennes; Rennes France
| | - R. Gressin
- Hématologie, CHU Grenoble; Grenoble France
| | - O. Hermine
- Hématologie, AP-HP Necker Paris; Paris France
| |
Collapse
|
10
|
Vallois D, Dupuy A, Lemonnier F, Fataccioli V, Ortonne N, Allen G, Tournilhac O, Delarue R, Rousselet-Chapeau M, Fabiani B, Llamas-Gutierrez F, Ko Y, Kataoka K, Gaulard P, de Leval L. TANSLOCATIONS INVOLVING CD28
ARE RARE IN PERIPHERAL T-CELL LYMPHOMAS. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_22] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- D. Vallois
- Institute of Pathology; Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| | - A. Dupuy
- Département de Pathologie, INSERM U955, Hôpital Henri-Mondor; Créteil France
| | - F. Lemonnier
- Département de Pathologie, INSERM U955, Hôpital Henri-Mondor; Créteil France
| | - V. Fataccioli
- Département de Pathologie, INSERM U955, Hôpital Henri-Mondor; Créteil France
| | - N. Ortonne
- Département de Pathologie, INSERM U955, Hôpital Henri-Mondor; Créteil France
| | - G. Allen
- Institute of Pathology; Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| | - O. Tournilhac
- Hématologie Clinique; CHU Estaing; Clermont-Ferrand France
| | - R. Delarue
- Hématologie Clinique; HU-Necker enfants malades; Paris France
| | | | - B. Fabiani
- Anatomie et Cytologie Pathologiques; Hôpital Saint-Antoine; Paris France
| | | | - Y.H. Ko
- Department of Pathology; Samsung Medical Center; Seoul South Korea
| | - K. Kataoka
- Department of Pathology and Tumor Biology; Kyoto University; Kyoto Japan
| | - P. Gaulard
- Département de Pathologie, INSERM U955, Hôpital Henri-Mondor; Créteil France
| | - L. de Leval
- Institute of Pathology; Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| |
Collapse
|
11
|
Lamy T, Damaj G, Soubeyran P, Gyan E, Legouill S, Cartron G, Boubdallah K, Gressin R, Cornillon J, Banos A, Ledu K, Benchalal M, Moles M, Fleury J, Godmer P, Maisonneuve H, Deconninck E, Laribi K, Marolleau J, Tournilhac O, Deviller A, Fest T, Colombat P, Costes V, Bene M, Delwail V. R-CHOP +/-RADIOTHERAPY IN NON-BULKY LIMITED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): FINAL RESULTS OF THE PROSPECTIVE RANDOMIZED PHASE III 02-03 TRIAL FROM THE LYSA/GOELAMS. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- T. Lamy
- Hematology; CHU de Rennes; Rennes France
| | - G. Damaj
- Hematology; CHU de Caen; Caen France
| | | | - E. Gyan
- Hematology; CHU de Tours; Tours France
| | | | - G. Cartron
- Hematology; CHU Montpellier; Montpellier France
| | | | - R. Gressin
- Hematology; CHU de Grenoble; Grenoble France
| | - J. Cornillon
- Hematology; Insitut de Cancerologie; Saint Etienne France
| | - A. Banos
- Hematology; CH BAyonne; Bayonne France
| | - K. Ledu
- Hematology; Clinique du Mans; Le Mans France
| | - M. Benchalal
- Radiotherapy; Centre Eugene Marquis; Rennes France
| | - M. Moles
- Hematology; CHU d'Angers; Angers France
| | - J. Fleury
- Hematology; Pole Sante Republique; Clermont Ferrand France
| | - P. Godmer
- Hematology; CH Vannes; Vannes France
| | - H. Maisonneuve
- Hematology; Centre Hospitalier de Vendee; La Roche sur Yon France
| | | | - K. Laribi
- Hematology; Le Mans Hospital; France
| | | | - O. Tournilhac
- Hematology; Clermont Hospital; Clermont Ferrand France
| | - A. Deviller
- Nuclear Medicine; Centre Eugene Marquis; France
| | - T. Fest
- Hematology Biology; CHU de Rennes; Rennes France
| | | | - V. Costes
- Pathology; CHU Montpellier; Montpellier France
| | - M. Bene
- Hematology Biology; CHU de Nantes; Nantes France
| | - V. Delwail
- Hematology; Poitiers Hospital; Poitiers France
| |
Collapse
|
12
|
Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, Lancesseur C, Lebras F, Willems E, Tchernonog E, Delarue R, Gressin R, Chauchet A, Gyan E, Cartron G, Bonnet C, Haioun C, Damaj G, Gaulard P, Fornecker L, Ghesquieres H, Tournilhac O, Gomes Da Silva M, Bouabdallah R, Salles G, Bachy E. ROLE OF UP-FRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMAS: a PROPENSITY SCORE MATCHING ANALYSIS OF PATIENTS FROM LYSA CENTERS. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_64] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- G. Fossard
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - F. Broussais
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - I. Coelho
- Hematology; Portuguese Institute of Oncology; Lisbon Portugal
| | - S. Bailly
- Hematology and Cell Therapy Department; Hôpital Estaing; Clermont-Ferrand France
| | | | - E. Toussaint
- Hematology; CHU de Strasbourg; Strasbourg France
| | | | - F. Lebras
- Lymphoid malignancies Unit; CHU Henri Mondor; Créteil France
| | | | | | - R. Delarue
- Hematology; CHU Necker Enfants Malades; Paris France
| | - R. Gressin
- Hematology; CHU Grenoble; Grenoble France
| | | | - E. Gyan
- Hematology; CHU de Tours; Tours France
| | - G. Cartron
- Hematology; CHU de Montpellier; Montpellier France
| | - C. Bonnet
- Hematology; CHU Liège; Liège Belgium
| | - C. Haioun
- Lymphoid malignancies Unit; CHU Henri Mondor; Créteil France
| | - G. Damaj
- Hematology; CHU de Caen; Caen France
| | - P. Gaulard
- Hematology; CHU Henri Mondor; Créteil France
| | - L. Fornecker
- Hematology; CHU de Strasbourg; Strasbourg France
| | - H. Ghesquieres
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - O. Tournilhac
- Hematology and Cell Therapy Department; Hôpital Estaing; Clermont-Ferrand France
| | | | | | - G. Salles
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - E. Bachy
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| |
Collapse
|
13
|
Clément M, Courouge-Dorcier D, Tournilhac O, Trouillier S. Histiocytose langheransienne cutanée et syndrome myélodysplasique : une association fortuite ? Rev Med Interne 2016. [DOI: 10.1016/j.revmed.2016.10.240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
Brotelle T, Cabrespine A, Combal C, Tournilhac O, Hermet E, Ravinet A, Bay JO, Bouteloup C. Prévalence de la dénutrition à distance d’une allogreffe de cellules souches hématopoïétiques chez l’adulte. NUTR CLIN METAB 2016. [DOI: 10.1016/j.nupar.2016.09.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
15
|
Zampaolo AS, Kanold J, Tournilhac O, Franck F, Bachelerie M, D'Incan M. Aggressive skin cancers in patients who experienced chronic GvHD after allogeneic bone marrow transplantation. Bone Marrow Transplant 2016; 52:130-131. [PMID: 27427917 DOI: 10.1038/bmt.2016.187] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A S Zampaolo
- Department of Dermatology, Université d'Auvergne, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - J Kanold
- Regional Center for Pediatric Cancerology and Cell Therapy, Université d'Auvergne, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - O Tournilhac
- Department of Hematology, Université d'Auvergne 1, CHU Clermont Ferrand, Clermont-Ferrand, France
| | - F Franck
- Department of Pathology, Université d'Auvergne 1, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - M Bachelerie
- Department of Pathology, Université d'Auvergne 1, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - M D'Incan
- Department of Dermatology, Université d'Auvergne, CHU Clermont-Ferrand, Clermont-Ferrand, France
| |
Collapse
|
16
|
Tessoulin B, Ceballos P, Chevallier P, Blaise D, Tournilhac O, Gauthier J, Maillard N, Tabrizi R, Choquet S, Carras S, Ifrah N, Guillerm G, Mohty M, Tilly H, Socie G, Cornillon J, Hermine O, Daguindau É, Bachy E, Girault S, Marchand T, Oberic L, Reman O, Leux C, Le Gouill S. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. Bone Marrow Transplant 2016; 51:1184-90. [PMID: 27111043 DOI: 10.1038/bmt.2016.102] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Revised: 03/06/2016] [Accepted: 03/08/2016] [Indexed: 11/09/2022]
Abstract
Poly-chemotherapy plus rituximab followed by autologous stem cell transplantation (auto-SCT) is standard care for untreated young patients with mantle cell lymphoma (MCL). Despite this intensive treatment, transplant patients remain highly susceptible to relapse over time. The French SFGM-TC performed a national survey on reduced-intensity conditioning allogeneic stem cell transplantation (RIC-allo-SCT) for fit relapsed/refractory patients who failed after auto-SCT (n=106). Median times of relapse after auto-SCT, and from auto-SCT to RIC-allo-SCT were 28 months and 3.6 years, respectively. Sixty per cent of patients received at least three lines of treatment before RIC-allo-SCT. Conditioning regimens for RIC-allo-SCT were heterogeneous. Twenty patients experienced grade III/IV aGvHD, extensive cGvHD was reported in 28 cases. Median follow-up after RIC-allo-SCT was 45 months. Median PFS after RIC-allo-SCT was 30.1 months and median overall survival was 62 months. Treatment-related mortality (TRM) at 1 year and 3 years were estimated at 28% and 32%, respectively. A total of 52 patients died; major causes of death were related to toxicity (n=34) and MCL (n=11). Patients in good response before RIC-allo-SCT experienced a better PFS and OS. Our work highlights the need for new RIC-allo-SCT MCL-tailored approaches to reduce TRM, and early and late relapse.
Collapse
Affiliation(s)
- B Tessoulin
- Department of Hematology, University Hospital, Nantes, France.,INSERM team 10 UMR 892, CRCNA, Nantes, France
| | - P Ceballos
- Department of Hematology, University Hospital, Montpellier, France
| | - P Chevallier
- Department of Hematology, University Hospital, Nantes, France
| | - D Blaise
- Department of Hematology, Paoli Calmettes, Marseille, France
| | - O Tournilhac
- Department of Hematology, University Hospital, Clermont-Ferrand, France
| | - J Gauthier
- Department of Hematology, University Hospital, Lille, France
| | - N Maillard
- Department of Hematology, University Hospital, Poitiers, France
| | - R Tabrizi
- Department of Hematology, University Hospital, Bordeaux, France
| | - S Choquet
- Department of Hematology, Pitie Salpetriere, Paris, France
| | - S Carras
- Department of Hematology, University Hospital, Grenoble, France
| | - N Ifrah
- Department of Hematology, University Hospital, Angers, France
| | - G Guillerm
- Department of Hematology, University Hospital, Brest, France
| | - M Mohty
- Department of Hematology, University Hospital-Saint Antoine, Paris, France
| | - H Tilly
- Department of Hematology, Centre Henri-Becquerel, Rouen, France
| | - G Socie
- Department of Hematology, Saint Louis Hospital, Paris, France
| | - J Cornillon
- Department of Hematology, Institut de Cancerologie de la Loire, Saint Etienne, France
| | - O Hermine
- Department of Hematology, Necker Hospital, Paris, France
| | - É Daguindau
- Department of Hematology, University Hospital, Besancon, France
| | - E Bachy
- Department of Hematology, University hospital, Lyon, France
| | - S Girault
- Department of Hematology, University Hospital, Limoges, France
| | - T Marchand
- Department of Hematology, University Hospital, Rennes, France
| | - L Oberic
- University Cancer Institute, Toulouse, France
| | - O Reman
- Department of Hematology, University Hospital, Caen, France
| | - C Leux
- Department of Epidemiology, University Hospital of Nantes, Nantes, France
| | - S Le Gouill
- Department of Hematology, University Hospital, Nantes, France.,INSERM team 10 UMR 892, CRCNA, Nantes, France.,Centre d'Investigation Clinique en Cancérologie (CI2C), CHU de Nantes, Nantes, France
| |
Collapse
|
17
|
Resseguier AS, André M, Orian Lazar EA, Bommelaer G, Tournilhac O, Delèvaux I, Ruivard M, D'Incan M, Boyer L, Aumaître O. [Natural history of portal cavernoma without liver disease. A single centre retrospective study of 32 cases]. Rev Med Interne 2015; 37:394-8. [PMID: 26387759 DOI: 10.1016/j.revmed.2015.07.017] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2014] [Revised: 07/05/2015] [Accepted: 07/31/2015] [Indexed: 01/16/2023]
Abstract
PURPOSE Portal cavernoma follows a chronic occlusion of the portal vein. The long-term consequences of portal cavernoma are not well known. The objective of this study was to report the aetiology of the portal cavernoma and its natural course after excluding liver diseases causes. METHODOLOGY A single centre retrospective study based on the data collected from the radiology department of the Clermont-Ferrand hospital was conducted from 2000 to 2011. All the patients for whom an imagery found a portal cavernoma have been looked for excluding the patients having a liver disease whatever the aetiology and the Budd-Chiari syndrome. RESULTS Thirty-two cases (18 women and 14 men) were selected. The mean age at diagnosis was 54.2 years and the mean follow-up period was 5.4 years. The discovery of a portal cavernoma was incidental for 8 cases. An aetiology was found for 24 cases: it was an haematological aetiology in 15 cases (10 myeloproliferative syndromes, 2 antiphospholid syndromes, 1 thalassemia major, 1 hyperhomocysteinemia, 1 prothrombin gene mutation), a general aetiology in 2 cases (1 coeliac disease, 1 pancreatic neoplasia), and a local inflammation in 7 cases. A dysmorphic aspect of the liver was noticed on medical imaging for 11 out of the 32 cases. A liver biopsy was performed in 4 patients and was normal for all of them. Sixteen patients developed oesophageal varices, 4 patients developed ascites, 3 developed asymptomatic biliary compression by the portal cavernoma, and the patient who had been followed for the longest time (15 years) developed an encephalopathy. CONCLUSION In addition to its underlying etiology, the prognosis of portal is mainly related to the occurrence of oesophageal varices that may develop during the follow-up of the patients.
Collapse
Affiliation(s)
- A S Resseguier
- Service de médecine interne, hôpital Gabriel-Montpied, CHU de Clermont-Ferrand, 58, rue Montalembert, 63003 Clermont-Ferrand cedex 1, France
| | - M André
- Service de médecine interne, hôpital Gabriel-Montpied, CHU de Clermont-Ferrand, 58, rue Montalembert, 63003 Clermont-Ferrand cedex 1, France; Faculté de médecine, université d'Auvergne, 63001 Clermont-Ferrand, France; Inserm, U1071, M2iSH, 63001 Clermont-Ferrand, France.
| | - E A Orian Lazar
- Service de radiologie, hôpital Gabriel-Montpied, CHU de Clermont-Ferrand, 63001 Clermont-Ferrand, France
| | - G Bommelaer
- Faculté de médecine, université d'Auvergne, 63001 Clermont-Ferrand, France; Inserm, U1071, M2iSH, 63001 Clermont-Ferrand, France; Service de gastroentérologie, hôpital Estaing, CHU de Clermont-Ferrand, 63003 Clermont-Ferrand, France
| | - O Tournilhac
- Faculté de médecine, université d'Auvergne, 63001 Clermont-Ferrand, France; Service d'hématologie, hôpital Estaing, CHU de Clermont-Ferrand, 63003 Clermont-Ferrand, France
| | - I Delèvaux
- Service de médecine interne, hôpital Gabriel-Montpied, CHU de Clermont-Ferrand, 58, rue Montalembert, 63003 Clermont-Ferrand cedex 1, France
| | - M Ruivard
- Faculté de médecine, université d'Auvergne, 63001 Clermont-Ferrand, France; Service de médecine interne, hôpital Estaing, CHU de Clermont-Ferrand, 63003 Clermont-Ferrand, France
| | - M D'Incan
- Faculté de médecine, université d'Auvergne, 63001 Clermont-Ferrand, France; Service de dermatologie, hôpital Estaing, CHU de Clermont-Ferrand, 63003 Clermont-Ferrand, France
| | - L Boyer
- Faculté de médecine, université d'Auvergne, 63001 Clermont-Ferrand, France; Service de radiologie, hôpital Gabriel-Montpied, CHU de Clermont-Ferrand, 63001 Clermont-Ferrand, France
| | - O Aumaître
- Service de médecine interne, hôpital Gabriel-Montpied, CHU de Clermont-Ferrand, 58, rue Montalembert, 63003 Clermont-Ferrand cedex 1, France; Faculté de médecine, université d'Auvergne, 63001 Clermont-Ferrand, France; Inserm, U1071, M2iSH, 63001 Clermont-Ferrand, France
| |
Collapse
|
18
|
Djelbani-Ahmed S, Chandesris MO, Mekinian A, Canioni D, Brouzes C, Hanssens K, Pop G, Durieu I, Durupt S, Grosbois B, Besnard S, Tournilhac O, Beyne-Rauzy O, Agapé P, Delmer A, Ranta D, Jeandel PY, Georgin-Lavialle S, Frenzel L, Damaj G, Eder V, Lortholary O, Hermine O, Fain O, Soussan M. FDG-PET/CT findings in systemic mastocytosis: a French multicentre study. Eur J Nucl Med Mol Imaging 2015; 42:2013-20. [PMID: 26140850 DOI: 10.1007/s00259-015-3117-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2015] [Accepted: 06/10/2015] [Indexed: 12/24/2022]
Abstract
INTRODUCTION Mastocytosis is a clonal haematological disease characterized by uncontrolled proliferation and the activation of mast cells. The value of FDG-PET/CT (FDG-PET) in mastocytosis has yet to be determined. METHODS We retrospectively identified patients with an established diagnosis of systemic mastocytosis (SM), according to the WHO criteria, who underwent PET using the French Reference Centre for Mastocytosis database. Semi-quantitative and visual analysis of FDG-PET was performed and compared to the clinico-biological data. RESULTS Our cohort included 19 adult patients, median age 65 years [range 58-74], including three with smouldering SM (SSM), three with aggressive SM (ASM), 10 with an associated clonal haematological non-mast-cell lineage disease (SM-AHNMD), and three with mast cell sarcoma (MCS). FDG-PET was performed at the time of the SM diagnosis (15/19), to evaluate lymph node (LN) activity (3/19) or the efficacy of therapy (1/19). FDG uptake was observed in the bone marrow (BM) (9/19, 47%), LN (6/19, 32%), spleen (12/19, 63%), or liver (1/19, 5%). No significant FDG uptake was observed in the SSM and ASM patients. A pathological FDG uptake was observed in the BM of 6/10 patients with SM-AHNMD, appearing as diffuse and homogeneous, and in the LN of 5/10 patients. All 3 MCS patients showed intense and multifocal BM pathological uptake, mimicking metastasis. No correlation was found between the FDG-PET findings and serum tryptase levels, BM mast cell infiltration percentage, and CD30 and CD2 expression by mast cells. CONCLUSIONS FDG uptake does not appear to be a sensitive marker of mast cell activation or proliferation because no significant FDG uptake was observed in most common forms of mastocytosis (notably purely aggressive SM). However, pathological FDG uptake was observed in the SM-AHNMD and in MCS cases, suggesting a role of FDG-PET in their early identification and as a tool of therapeutic assessment in this subgroup of patients.
Collapse
Affiliation(s)
- S Djelbani-Ahmed
- Department of Nuclear Medicine, Avicenne Hospital, Assistance Publique - Hôpitaux de Paris (APHP), Bobigny, France
- Sorbonne Paris Cité, Paris 13 University, Bobigny, France
| | - M O Chandesris
- French Reference center for Mastocytosis (Centre de Référence des Mastocytoses, CEREMAST), Necker Children's Hospital, APHP, Paris, France
- Department of Haematology, Necker Children's Hospital, APHP, Paris, France
- Sorbonne Paris Cité, Imagine Institute, Paris Descartes University, Paris, France
| | - A Mekinian
- Department of Internal Medicine and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), AP-HP, Saint Antoine Hospital, Paris, France
| | - D Canioni
- French Reference center for Mastocytosis (Centre de Référence des Mastocytoses, CEREMAST), Necker Children's Hospital, APHP, Paris, France
- Sorbonne Paris Cité, Imagine Institute, Paris Descartes University, Paris, France
- Department of Pathology, Necker Children's Hospital, APHP, Paris, France
| | - C Brouzes
- French Reference center for Mastocytosis (Centre de Référence des Mastocytoses, CEREMAST), Necker Children's Hospital, APHP, Paris, France
- Sorbonne Paris Cité, Imagine Institute, Paris Descartes University, Paris, France
- Laboratory of Haematology, Necker Children's Hospital, APHP, Paris, France
| | - K Hanssens
- French Reference center for Mastocytosis (Centre de Référence des Mastocytoses, CEREMAST), Necker Children's Hospital, APHP, Paris, France
- INSERM U1068, Centre de Recherche en Cancérologie de Marseille (Signaling, Hematopoiesis and Mechanism of Oncogenesis), Paoli Calmettes Institute, Aix-Marseille University, Marseille, France
| | - G Pop
- Department of Nuclear Medicine, Avicenne Hospital, Assistance Publique - Hôpitaux de Paris (APHP), Bobigny, France
| | - I Durieu
- Department of Internal and Vascular Medicine, Hospices Civils de Lyon, Groupe Hopitalier Sud, Université de Lyon, Pierre-Bénite, France
| | - S Durupt
- Department of Internal and Vascular Medicine, Hospices Civils de Lyon, Groupe Hopitalier Sud, Université de Lyon, Pierre-Bénite, France
| | - B Grosbois
- Department of Internal Medicine, Rennes University Hospital, Rennes, France
| | - S Besnard
- Department of Internal Medicine, Rennes University Hospital, Rennes, France
| | - O Tournilhac
- Department of Internal Medicine, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - O Beyne-Rauzy
- Department of Internal Medicine, Purpan University Hospital, Toulouse, France
| | - P Agapé
- Department of Oncology and Haematology, Saint-Denis University Hospital, Saint-Denis de la Réunion, France
| | - A Delmer
- Department of Haematology, Reims University Hospital, Reims, France
| | - D Ranta
- Department of Haematology, Brabois University Hospital, Vandoeuvre les Nancy, France
| | - P Y Jeandel
- Department of Internal Medicine, Nice University Hospital, Nice, France
| | | | - L Frenzel
- French Reference center for Mastocytosis (Centre de Référence des Mastocytoses, CEREMAST), Necker Children's Hospital, APHP, Paris, France
- Department of Haematology, Necker Children's Hospital, APHP, Paris, France
- Sorbonne Paris Cité, Imagine Institute, Paris Descartes University, Paris, France
| | - G Damaj
- French Reference center for Mastocytosis (Centre de Référence des Mastocytoses, CEREMAST), Necker Children's Hospital, APHP, Paris, France
- Department of Haematology, Caen University Hospital, Caen, France
| | - V Eder
- Department of Nuclear Medicine, Avicenne Hospital, Assistance Publique - Hôpitaux de Paris (APHP), Bobigny, France
| | - O Lortholary
- French Reference center for Mastocytosis (Centre de Référence des Mastocytoses, CEREMAST), Necker Children's Hospital, APHP, Paris, France
- Sorbonne Paris Cité, Imagine Institute, Paris Descartes University, Paris, France
- Department of Infectious Diseases and Tropical Medicine, Necker Children's Hospital, APHP, Pasteur Institute, Paris, France
| | - O Hermine
- French Reference center for Mastocytosis (Centre de Référence des Mastocytoses, CEREMAST), Necker Children's Hospital, APHP, Paris, France
- Department of Haematology, Necker Children's Hospital, APHP, Paris, France
- Sorbonne Paris Cité, Imagine Institute, Paris Descartes University, Paris, France
| | - O Fain
- Department of Internal Medicine and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), AP-HP, Saint Antoine Hospital, Paris, France
| | - M Soussan
- Department of Nuclear Medicine, Avicenne Hospital, Assistance Publique - Hôpitaux de Paris (APHP), Bobigny, France.
- Sorbonne Paris Cité, Paris 13 University, Bobigny, France.
| |
Collapse
|
19
|
Joubert R, Bonnin N, Kemeny JL, Moluçon-Chabrot C, Tournilhac O, Bacin F, Chiambaretta F. [Intraocular lymphoma associated with primary malignant lymphoma of the central nervous system: Seven-year experience of a tertiary center]. J Fr Ophtalmol 2015; 38:559-66. [PMID: 25976140 DOI: 10.1016/j.jfo.2015.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2015] [Revised: 03/17/2015] [Accepted: 03/20/2015] [Indexed: 10/23/2022]
Abstract
INTRODUCTION Primary intraocular lymphoma (PIOL), associated with primary central nervous system lymphoma (PCNSL), is a rare malignancy disease. By way of a seven-year experience of a tertiary center, we discuss the presentation and we review the diagnostic and therapeutic modalities. OBSERVATIONS We report six cases of PIOL associated with PCNSL. For all patients, the clinical presentation was a vitreoretinal syndrome. The diagnosis was histologically confirmed by vitreal sample or brain biopsy. Five patients developed a diffuse large B-cell lymphoma. Only one patient developed a T-cell lymphoma. The treatment consisted of conformational radiation therapy, systemic chemotherapy and intravitreal injections of methotrexate. The median survival after the diagnosis was 24 months. DISCUSSION PIOL, associated with PCNSL, is the most common type of ocular lymphoma. In most cases, ocular manifestations inaugurate the disease. PIOL is often fatal because of ultimate central nervous system presentation. The role of the ophthalmologist consists in early diagnosis. Typical clinical findings include vitroretinal tumor syndrome but can mascarade other eye pathologies. Diagnosis requires histology. The majority of PIOL is diffused large B-cell lymphoma. Decisions are made through multidisciplinary consultation. PIOL exhibits high responsiveness to methotrexate. CONCLUSION Through a literature review and many illustrations, we discuss epidemiological, clinical, histological, radiological and treatment characteristics of PIOL associated with PCNSL.
Collapse
Affiliation(s)
- R Joubert
- Service d'ophtalmologie, pôle médecine interne-ophtalmologie-ORL, CHU de Clermont-Ferrand, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| | - N Bonnin
- Service d'ophtalmologie, pôle médecine interne-ophtalmologie-ORL, CHU de Clermont-Ferrand, 58, rue Montalembert, 63000 Clermont-Ferrand, France; EA 7281 R2D2, Biochemistry Laboratory, Medicine Faculty, Auvergne University, 28, place Henri-Dunant, 63001 Clermont-Ferrand, France.
| | - J-L Kemeny
- Service anatomopathologie, centre de biochimie, CHU de Clermont-Ferrand, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| | - C Moluçon-Chabrot
- Hématologie clinique, CHU de Clermont-Ferrand, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| | - O Tournilhac
- Hématologie clinique, CHU de Clermont-Ferrand, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| | - F Bacin
- Service d'ophtalmologie, pôle médecine interne-ophtalmologie-ORL, CHU de Clermont-Ferrand, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| | - F Chiambaretta
- Service d'ophtalmologie, pôle médecine interne-ophtalmologie-ORL, CHU de Clermont-Ferrand, 58, rue Montalembert, 63000 Clermont-Ferrand, France; EA 7281 R2D2, Biochemistry Laboratory, Medicine Faculty, Auvergne University, 28, place Henri-Dunant, 63001 Clermont-Ferrand, France
| |
Collapse
|
20
|
Bouabdallah K, Furst S, Asselineau J, Chevalier P, Tournilhac O, Ceballos P, Vigouroux S, Tabrizi R, Doussau A, Bouabdallah R, Mohty M, Le Gouill S, Blaise D, Milpied N. 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas. Ann Oncol 2015; 26:193-198. [PMID: 25361987 DOI: 10.1093/annonc/mdu503] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Patients with advanced B-cell non-Hodgkin's lymphoma (NHL) refractory to initial chemotherapy or relapsing after autologous stem-cell transplantation have a poor prognosis. Allogeneic stem-cell transplantation after reduced-intensity conditioning (RIC) regimen can be a therapeutic option. However, the high incidence of relapse remains a challenging issue. We speculated that the incorporation of (90)Y-Ibritumomab tiuxetan into a fludarabine-based RIC regimen would improve the lymphoma control without overwhelming toxicity. Our aim was to evaluate the safety of (90)Y-Ibritumomab tiuxetan in association with such a regimen in a prospective multicenter phase II trial. PATIENTS AND METHODS Thirty-one patients with advanced lymphoma from five distinct institutions were included between February 2008 and October 2010. Thirty patients in complete or partial response after failure of a median of 3 (range, 2-4) previous chemotherapy regimens including autologous transplant in 29 were evaluable for nonrelapse mortality (NRM) at day 100 post-transplant that was the primary end point. RESULTS With a median follow-up of 32 months (range, 29-60 months), the 2-year event-free and overall survivals of the whole study group were both 80% [95 confidence interval (CI) 60.8% to 90.5%). The 100-day and 2-year post-transplant cumulative incidences of NRM were 3.3% (95% CI 0.2% to 14.9%) and 13.3% (95% CI 5.4% to 33.2%), respectively. The 2-year cumulative incidence of relapse was 6.7% (95% CI 1.7% to 25.4%). The cumulative incidences of grade II-IV and extensive chronic graft-versus-host disease were 27% and 14%, respectively. CONCLUSIONS For chemosensitive advanced high-risk B-cell lymphoma, the addition of (90)Y-Ibritumomab tiuxetan to a RIC regimen based on fludarabine, busulfan and antithymocyte globulin followed by allogeneic transplant is safe and highly effective. clinicaltrials.gov: NCT00607854.
Collapse
Affiliation(s)
- K Bouabdallah
- Department of Hematology and Cellular Therapy, Haut-Leveque University Hospital, Bordeaux.
| | - S Furst
- Department of Hematology, Institut Paoli Calmettes, Marseille
| | - J Asselineau
- Methodological Support Unit in Clinical and Epidemiological Research (USMR), University Hospital, Bordeaux; Department of National Health Institute and Medical Research (INSERM U897, CIC-EC7), Bordeaux
| | - P Chevalier
- Department of Hematology, University Hospital, Nantes
| | - O Tournilhac
- Department of Hematology, University Hospital, Clermont-Ferrand
| | - P Ceballos
- Department of Hematology, University Hospital, Montpellier
| | - S Vigouroux
- Department of Hematology and Cellular Therapy, Haut-Leveque University Hospital, Bordeaux
| | - R Tabrizi
- Department of Hematology and Cellular Therapy, Haut-Leveque University Hospital, Bordeaux
| | - A Doussau
- Methodological Support Unit in Clinical and Epidemiological Research (USMR), University Hospital, Bordeaux; Department of National Health Institute and Medical Research (INSERM U897, CIC-EC7), Bordeaux; Medical School Department, Bordeaux Segalen University, Bordeaux
| | - R Bouabdallah
- Department of Hematology, Institut Paoli Calmettes, Marseille
| | - M Mohty
- Department of Hematology, Saint-Antoine University Hospital, Paris
| | - S Le Gouill
- Department of Hematology, University Hospital, Nantes; Department of National Health Institute and Medical Research (INSERM, UMR 892), Team 10, Nantes, France
| | - D Blaise
- Department of Hematology, Institut Paoli Calmettes, Marseille
| | - N Milpied
- Department of Hematology and Cellular Therapy, Haut-Leveque University Hospital, Bordeaux; Medical School Department, Bordeaux Segalen University, Bordeaux
| |
Collapse
|
21
|
Fraisse T, Hery L, Samou F, Rieu V, Ruivard M, Buisson A, Tournilhac O, Kahn J, Trouillier S. Éosinophilie majeure révélant une rectocolite hémorragique. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.03.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
22
|
Houot R, Le Gouill S, Ojeda Uribe M, Mounier C, Courby S, Dartigeas C, Bouabdallah K, Alexis Vigier M, Moles M, Tournilhac O, Arakelyan N, Rodon P, El Yamani A, Sutton L, Fornecker L, Assouline D, Harousseau J, Maisonneuve H, Caulet-Maugendre S, Gressin R. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. Ann Oncol 2012; 23:1555-61. [DOI: 10.1093/annonc/mdr450] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Le Gouill S, Kröger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I, Kanouni T, Bulabois CE, Tournilhac O, Buzyn A, Rio B, Moles MP, Shimoni A, Bacher U, Ocheni S, Milpied N, Harousseau JL, Moreau P, Leux C, Mohty M. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 2012; 23:2695-2703. [PMID: 22440229 DOI: 10.1093/annonc/mds054] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
BACKGROUND Despite therapeutic approach that combines rituximab-containing chemotherapy, followed or not by autologous stem cell transplantation (auto-SCT), mantle cell lymphoma (MCL) patients experience relapses. Reduced-intensity conditioning allogeneic stem cell transplantation (RIC-allo-SCT) at time of relapse may represent an attractive strategy. PATIENTS AND METHODS We report a multicenter retrospective analysis. Seventy MCL patients underwent RIC-allo-SCT in 12 centers. RESULTS Median age at transplantation was 56 years and median time from diagnosis to transplantation was 44 months. The median number of previous therapies was 2 (range, 1-5) including autologous transplantation in 47 cases. At time of transplantation, 35 patients were in complete remission, 20 were in partial response and 15 in stable disease or progressive disease. The median follow-up for living patients was 24 months. The 2-year event-free survival (EFS) and overall survival (OS) rates were 50% and 53%, respectively. The 1- and 2-year transplant-related mortality rates were 22% and 32%, respectively. The statistical analysis demonstrated that disease status at transplantation was the only parameter influencing EFS and OS. CONCLUSIONS These results suggest that RIC-allo-SCT may be an effective therapy in MCL patients with a chemo-sensitive disease at time of transplantation, irrespective of the number of lines of prior therapy. Studies are warranted to investigate the best type of RIC regimen.
Collapse
Affiliation(s)
- S Le Gouill
- Division of Hematology, University of Nantes, Hôtel-Dieu, Nantes; Centre de recherches en Cancérologie Nantes/Angers, INSERM, UMR 892, équipe 10, UFR Médecine et Techniques Médicales, Université de Nantes, Nantes; Centre d'Investigation Clinique en Cancérologie (CI2C); Unité de Recherche clinique en onco-hématologie, University of Nantes, Nantes, France.
| | - N Kröger
- Bone Marrow Transplantation Unit, University of Hamburg, Hamburg, Germany
| | - N Dhedin
- Hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France
| | - A Nagler
- Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel
| | - K Bouabdallah
- Division of Hematology, University of Bordeaux, Pessac
| | | | - T Kanouni
- Division of Hematology, University of Montpellier, Montpellier
| | | | - O Tournilhac
- Division of Hematology, University of Clermont-Ferrand, Clermont-Ferrand
| | - A Buzyn
- Hôpital Necker-Enfants malades
| | | | - M P Moles
- Division of Hematology, University of Angers, Angers
| | - A Shimoni
- Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel
| | - U Bacher
- Bone Marrow Transplantation Unit, University of Hamburg, Hamburg, Germany
| | - S Ocheni
- Bone Marrow Transplantation Unit, University of Hamburg, Hamburg, Germany
| | - N Milpied
- Division of Hematology, University of Bordeaux, Pessac
| | | | - P Moreau
- Division of Hematology, University of Nantes, Hôtel-Dieu, Nantes; Unité de Recherche clinique en onco-hématologie, University of Nantes, Nantes, France
| | - C Leux
- Cancer Registry of Loire-Atlantique and Vendée, Nantes, France
| | - M Mohty
- Division of Hematology, University of Nantes, Hôtel-Dieu, Nantes; Centre d'Investigation Clinique en Cancérologie (CI2C); Unité de Recherche clinique en onco-hématologie, University of Nantes, Nantes, France
| |
Collapse
|
24
|
Resseguier A, Grobost V, Samou F, Delèvaux I, Guettrot-Imbert G, Tournilhac O, Trouillier S, Aumaitre O. Une dermatomyosite révélant un syndrome myélodysplasique 5q-. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
25
|
Makarawiez C, Le Guenno G, Rieu V, Tournilhac O, Philippe P, Ruivard M. Thromboses et purpura thrombopénique immunologique. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.10.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
26
|
Gironde M, Domaison S, Bézy O, Van Lander A, Planche F, Fradin A, Nore F, Fédor MC, Leyssène-Ouvrard C, Amblard-Manhes E, Brugnon D, Tournilhac O, Bay JO, Travade P, Jalenques I. Étude intégrant les proches aux soins en cancérologie: résultats qualitatifs, perspectives et limites. PSYCHO-ONCOLOGIE 2010. [DOI: 10.1007/s11839-010-0288-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
27
|
Courbil R, Romaszko JP, Odent-Malaure H, Fabrigli P, Chavarin P, Tournilhac O, Bay JO, Fressy P, Ergani A, Bouvet A, Bonnet R, Garraud O. Analyse d’un incident bactérien grave transmis par transfusion d’un concentré plaquettaire. Transfus Clin Biol 2010; 17:9-13. [DOI: 10.1016/j.tracli.2009.12.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2009] [Accepted: 12/11/2009] [Indexed: 11/25/2022]
|
28
|
Bay JO, Tournilhac O, Ducher E, Romaszko JP, Ergani A, Bouvet A, Fabrigli P, Odent-Malaure H, Courbil R, Garraud O. A near fatal septic transfusion reaction due to Streptococcus dysgalactiae subspecies equisimilis calls for novel safety measures. Vox Sang 2009; 96:271. [PMID: 19522886 DOI: 10.1111/j.1423-0410.2008.001150.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Rieu V, Ruivard M, Chaleteix C, Tournilhac O, Philippe P. Purpura thrombopénique immunologique chez les patients âgés. Rev Med Interne 2008. [DOI: 10.1016/j.revmed.2008.10.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
30
|
Berger MG, Berger J, Richard C, Jeanpierre S, Nicolini FE, Tournilhac O, Michallet M, Satta VM. Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization. Leukemia 2008; 22:2131-4. [DOI: 10.1038/leu.2008.167] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
31
|
Bocquier B, D’Incan M, Joubert J, Kanitakis J, Salavert M, Tournilhac O, Maitre F, Déchelotte P, Souteyrand P, Estève E, Martin L. Amyloid elastosis: a new case studied extensively by electron microscopy and immunohistochemistry. Br J Dermatol 2008; 158:858-60. [DOI: 10.1111/j.1365-2133.2007.08428.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
32
|
Roszyk L, Faye B, Tournilhac O, Fogli A, Sapin V. [Monoclonal IgM interference with immunoturbidimetric determination of ferritin and transferrin]. Ann Biol Clin (Paris) 2007; 65:659-662. [PMID: 18039612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2007] [Accepted: 08/28/2007] [Indexed: 05/25/2023]
Abstract
When they are present in important blood concentration, the monoclonal immunoglobulins are known to interfere with many immuno-analyze assays. We report the case of a patient presenting a Waldenstrom macroglobulinemia, for which the determination of some parameters of the martial assessment was impossible because of the presence of IgM kappa. The analysis of analytical alarms of the automat as well as the installation of simple and fast pre-treatment protocol of the interference enabled us to quickly make a result useful for the management of this patient.
Collapse
Affiliation(s)
- L Roszyk
- Laboratoire de biochimie médicale, CHU de Clermont-Ferrand
| | | | | | | | | |
Collapse
|
33
|
Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lhéritier V, Vernant JP, Dombret H, Thomas X. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007; 21:1907-14. [PMID: 17611565 DOI: 10.1038/sj.leu.2404824] [Citation(s) in RCA: 193] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Fifty-four percent of adults with acute lymphoblastic leukemia (ALL) who entered the LALA-94 trial experienced a first relapse. We examined the outcome of these 421 adult patients. One hundred and eighty-seven patients (44%) achieved a second complete remission (CR). The median disease-free survival (DFS) was 5.2 months with a 5-year DFS at 12%. Factors predicting a better outcome after relapse were any transplant performed in second CR (P<0.0001), a first CR duration >1 year (P=0.04) and platelet level >100 x 10(9)/l at relapse (P=0.04). Risk groups defined at diagnosis and treatment received in first CR did not influence the outcome after relapse. The best results were obtained in a subset of patients who were eligible for allogeneic stem cell transplantation (SCT). Geno-identical allogeneic SCT was performed in 55 patients, and 3 patients received donor lymphocyte infusions. Forty-four transplantations were performed from an unrelated donor (of which four were cord blood). We conclude that most adult patients with recurring ALL could not be rescued using current available therapies, although allogeneic SCT remains the best therapeutic option.
Collapse
|
34
|
Vey N, Thomas X, Picard C, Kovascovicz T, Charin C, Cayuela JM, Dombret H, Dastugue N, Huguet F, Bastard C, Stamatoulas A, Giollant M, Tournilhac O, Macintyre E, Buzyn A, Bories D, Kuentz M, Dreyfus F, Delannoy A, Raynaud S, Gratecos N, Bordessoule D, de Botton S, Preudhomme C, Reman O, Troussard X, Pigneux A, Bilhou C, Vernant JP, Boucheix C, Gabert J. Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia 2006; 20:2155-61. [PMID: 17039234 DOI: 10.1038/sj.leu.2404420] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2006] [Revised: 08/23/2006] [Accepted: 08/25/2006] [Indexed: 11/09/2022]
Abstract
Adult patients with acute lymphoblastic leukemia (ALL) and t(1;19)/E2A-PBX1 or t(4;11)/MLL-AF4 have a poor outcome. We have evaluated the impact of an intensified post-remission therapy using a high-dose chemotherapy course followed by allogeneic or autologous SCT on the outcome of 58 patients with t(1;19)/E2A-PBX1 (E2A group, n=24) or t(4;11)/MLL-AF4 (MLL group, n=34) treated in the LALA-94 multicenter prospective study. Patients in the MLL group had higher WBC counts and more frequent DIC. CR rates achieved by MLL and E2A groups were similar to other B-cell ALL (87, 82 and 86% respectively). While in CR, patients with a donor were assigned to alloSCT (n=22), the remaining patients with were randomized between autoSCT (n=15) or chemotherapy (n=8). Five-year overall survival was 31 and 45% for E2A and MLL groups, respectively. In both groups, DFS was higher in the alloSCT arm as compared to autoSCT and chemotherapy arms. The results of this study show that chemotherapy intensification did not overcome the poor prognosis of adults with t(1;19)/E2A-PBX1. Allogeneic SCT should thus be offered in first CR to patients with t(1;19)/E2A-PBX1 or t(4;11)/MLL-AF4. New therapeutic approaches are needed for patients without donor.
Collapse
MESH Headings
- Adolescent
- Adult
- Basic Helix-Loop-Helix Transcription Factors/genetics
- Burkitt Lymphoma/genetics
- Burkitt Lymphoma/therapy
- Chromosomes, Human, Pair 1/genetics
- Chromosomes, Human, Pair 11/genetics
- Chromosomes, Human, Pair 19/genetics
- Chromosomes, Human, Pair 4/genetics
- DNA-Binding Proteins/genetics
- Female
- Hematopoietic Stem Cell Transplantation
- Histone-Lysine N-Methyltransferase
- Humans
- Male
- Middle Aged
- Myeloid-Lymphoid Leukemia Protein/genetics
- Nuclear Proteins/genetics
- Pre-B-Cell Leukemia Transcription Factor 1
- Prospective Studies
- Proto-Oncogene Proteins/genetics
- Transcriptional Elongation Factors
- Translocation, Genetic
- Transplantation, Homologous
Collapse
Affiliation(s)
- N Vey
- Département of Hematology, The Institut Paoli-Calmettes, Marseille, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Tournilhac O, Santos DD, Xu L, Kutok J, Tai YT, Le Gouill S, Catley L, Hunter Z, Branagan AR, Boyce JA, Munshi N, Anderson KC, Treon SP. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol 2006; 17:1275-82. [PMID: 16788002 DOI: 10.1093/annonc/mdl109] [Citation(s) in RCA: 103] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Bone marrow (BM) mast cells (MC) are commonly found in association with lymphoplasmacytic cells (LPC) in patients with Waldenström's macroglobulinemia (WM). We therefore sought to clarify the role of MC in WM. Co-culture of sublethally irradiated HMC-1 MC, KU812 basophilic cells, or autologous BM MC along with BM LPC from WM patients resulted in MC dose-dependent tumor colony formation and/or proliferation as assessed by 3H-thymidine uptake studies. Furthermore, by immunohistochemistry, multicolor flow cytometry and/or RT-PCR analysis, CD40 ligand (CD154), a potent inducer of B-cell expansion, was expressed on BM MC from 32 of 34 (94%), 11 of 13 (85%), and 7 of 9 (78%) patients, respectively. In contrast, MC from five healthy donors did not express CD154. By multicolor flow cytometry, CD154 was expressed on BM LPC from 35 of 38 (92%) patients and functionality was confirmed by CD154 and CD40 agonistic antibody stimulation, which induced proliferation, support survival and/or pERK phosphorylation of LPC. Moreover, MC induced expansion of LPC from 3 of 5 patients was blocked in a dose dependent manner by use of a CD154 blocking protein. These studies demonstrate that in WM, MC may support tumor cell expansion through constitutive CD154-CD40 signaling and therefore provide the framework for therapeutic targeting of MC and MC-WM cell interactions in WM.
Collapse
Affiliation(s)
- O Tournilhac
- Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02115, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C, Santos DD, Hatjiharissi E, Xu L, Leleu X, Tournilhac O, Patterson CJ, Manning R, Branagan AR, Morton CC. Characterization of familial Waldenström's macroglobulinemia. Ann Oncol 2006; 17:488-94. [PMID: 16357024 DOI: 10.1093/annonc/mdj111] [Citation(s) in RCA: 146] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Familial clustering of B-cell disorders among Waldenström's macroglobulinemia (WM) patients has been reported, though the frequency and any differences in disease manifestation for familial patients remain to be defined. PATIENTS AND METHODS We therefore analyzed clinicopathological data from 257 consecutive and unrelated WM patients. Forty-eight (18.7%) patients had at least one first-degree relative with either WM (n = 13, 5.1%), or another B-cell disorder including non-Hodgkin's lymphoma (n = 9, 3.5%), myeloma (n = 8, 3.1%), chronic lymphocytic leukemia (n = 7, 2.7%), monoclonal gammopathy of unknown significance (n = 5, 1.9%), acute lymphocytic leukemia (n = 3, 1.2%) and Hodgkin's disease (n = 3, 1.2%). Patients with a familial history of WM or a plasma cell disorder (PCD) were diagnosed at a younger age and with greater bone marrow involvement. RESULTS Deletions in 6q represented the only recurrent structural chromosomal abnormality and were found in 13% of patients, all non-familial cases. Interphase FISH analysis demonstrated deletions in 6q21-22.1 in nearly half of patients, irrespective of familial background. CONCLUSIONS The above results suggest a high degree of clustering for B-cell disorders among first-degree relatives of patients with WM, along with distinct clinical features at presentation based on familial disease cluster patterns. Genomic studies to delineate genetic predisposition to WM are underway.
Collapse
Affiliation(s)
- S P Treon
- Bing Center for Waldenström's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02115, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Jacomet C, Lesens O, Villemagne B, Darcha C, Tournilhac O, Henquell C, Cormerais L, Gourdon F, Peigue-Lafeuille H, Travade P, Beytout J, Laurichesse H. Lymphomes non hodgkiniens et hodgkiniens et infection VIH : fréquence, pronostic et reconstitution immune sous trithérapie antirétrovirale ; CHU de Clermont-Ferrand, 1991–2003. Med Mal Infect 2006; 36:157-62. [PMID: 16503104 DOI: 10.1016/j.medmal.2005.11.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2005] [Accepted: 11/24/2005] [Indexed: 11/18/2022]
Abstract
OBJECTIVES The authors had for aim to identify cases of non Hodgkin's (NHL) and Hodgkin's (HL) lymphomas in HIV1-infected patients to assess 1) their incidence, before and after 1996, 2) the clinical features and outcome under treatment together with the survival rate of the patients, 3) the immune reconstitution of lymphoma-free patients under HAART. PATIENTS AND METHODS A retrospective study was made of HIV1-infected patients managed at the Clermont-Ferrand University Hospital from 1991 to 2003 for the diagnosis and treatment of HIV1-related lymphomas. RESULTS Forty-one patients were included: 35 NHL and 6 HL giving a cumulative incidence rate estimate from 2.4% between 1991 and 1996 to 3.4% between 1997 and 2003 while other opportunistic diseases were decreasing. A high proportion of aggressive and disseminated disease was observed among NHL cases. Complete remission was achieved in 17 (49%) and 5 (83%) NHL and HL cases respectively. The mean survival was 109+/-54 months and was correlated with CD4 cell count at lymphoma diagnosis (univariate analysis). Among responding patients, 5 died: 3 from opportunistic infections, 1 commited suicide, and 1 from hepatic carcinoma. For responding patients, the mean increase of CD4 cell count under HAART was 58/mm3 over a 2 year-period and 192/mm3 over a 5 year-period of follow-up. CONCLUSIONS The incidence of lymphomas in HIV-infected patients has not decreased since the introduction of HAART. The immune status assessed by CD4 cell count on diagnosis is correlated with survival. Immune restoration in lymphoma-free patients under HAART is poor.
Collapse
Affiliation(s)
- C Jacomet
- Service des maladies infectieuses et tropicales, CHU de Clermont-Ferrand, BP 69, 63000 Clermont-Ferrand, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Tchirkov A, Chaleteix C, Magnac C, Vasconcelos Y, Davi F, Michel A, Kwiatkowski F, Tournilhac O, Dighiero G, Travade P. hTERT expression and prognosis in B-chronic lymphocytic leukemia. Ann Oncol 2004; 15:1476-80. [PMID: 15367406 DOI: 10.1093/annonc/mdh389] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND In B-chronic lymphocytic leukemia (B-CLL), there is a need for molecular markers to predict the evolution of this heterogeneous disease in individual patients. The level of expression of the human telomerase reverse transcriptase (hTERT) gene has been associated with disease aggressiveness in human cancers. The purpose of the present study was to examine the prognostic significance of hTERT expression in B-CLL. PATIENTS AND METHODS We used real-time reverse transcription-PCR to quantitate the amount of hTERT transcripts in mononuclear blood cells from 90 B-CLL patients. In addition, samples were analyzed for somatic mutations in the immunoglobulin V (IgV) genes. RESULTS The expression of hTERT gene was detected in 59% of patients. The level of expression increased with advancing B-CLL stage (P=0.0064). Patients expressing hTERT showed significantly shorter survival than hTERT-negative patients (P=0.000034), irrespective of the disease stage. On average, the level hTERT mRNA expression was seven-fold higher in the poor-prognosis B-CLL group with unmutated IgV than in the Ig-mutated group (P<10(-7)). The level of hTERT expression discriminated the Ig-unmutated from Ig-mutated B-CLL in 89% of cases. CONCLUSION Our data indicate that hTERT expression in B-CLL may serve as a molecular prognostic marker.
Collapse
Affiliation(s)
- A Tchirkov
- Service d'Hématologie Clinique, CHU, Clermont-Ferrand.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Cafarella T, Manning R, Hunter Z, Branagan AR, Tournilhac O, Santos DD, Dorfman DM, Treon SP. Heterogeneous expression of CD5, CD10, and CD23 in Waldenstrom's macroglobulinemia. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- T. Cafarella
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - R. Manning
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - Z. Hunter
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - A. R. Branagan
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - O. Tournilhac
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - D. D. Santos
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - D. M. Dorfman
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - S. P. Treon
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| |
Collapse
|
40
|
Manning R, Branagan AR, Hunter Z, Tournilhac O, Santos DD, Treon SP. Characterization of familial Waldenstrom's Macroglobulinemia. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. Manning
- Dana Farber Cancer Institute, Boston, MA
| | | | - Z. Hunter
- Dana Farber Cancer Institute, Boston, MA
| | | | | | | |
Collapse
|
41
|
Tournilhac O, Ditzel Santos D, Branagan A, Hunter Z, Manning R, Tai YT, Kutok JL, Munshi N, Anderson KC, Treon SP. Excess bone marrow mast cells constitutively express CD154 (CD40 ligand) in Waldenstrom's macroglobulinemia and may support tumor cell growth through CD154/CD40 pathway. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- O. Tournilhac
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - D. Ditzel Santos
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - A. Branagan
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - Z. Hunter
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - R. Manning
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - Y.-T. Tai
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - J. L. Kutok
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - N. Munshi
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - K. C. Anderson
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - S. P. Treon
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| |
Collapse
|
42
|
Milpied NJ, Lamy T, Casassus P, Deconninck E, Gressin R, Le Maignan C, Tournilhac O, Dugay J, Legouffe E, Delwail V. Front-line high-dose chemotherapy (HDT) combined with rituximab for adults with aggressive large B cell lymphoma (DLBCL). A pilot study by the GOELAMS. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- N. J. Milpied
- university hospital, nantes, France; university hospital, rennes, France; hospital, bobigny, France; university hospital, besancon, France; university hospital, grenoble, France; georges pompidou european hospital, paris, France; university hospital, clermont-ferrand, France; hospital, le mans, France; university hospital, montpellier, France; university hospital, poitiers, France
| | - T. Lamy
- university hospital, nantes, France; university hospital, rennes, France; hospital, bobigny, France; university hospital, besancon, France; university hospital, grenoble, France; georges pompidou european hospital, paris, France; university hospital, clermont-ferrand, France; hospital, le mans, France; university hospital, montpellier, France; university hospital, poitiers, France
| | - P. Casassus
- university hospital, nantes, France; university hospital, rennes, France; hospital, bobigny, France; university hospital, besancon, France; university hospital, grenoble, France; georges pompidou european hospital, paris, France; university hospital, clermont-ferrand, France; hospital, le mans, France; university hospital, montpellier, France; university hospital, poitiers, France
| | - E. Deconninck
- university hospital, nantes, France; university hospital, rennes, France; hospital, bobigny, France; university hospital, besancon, France; university hospital, grenoble, France; georges pompidou european hospital, paris, France; university hospital, clermont-ferrand, France; hospital, le mans, France; university hospital, montpellier, France; university hospital, poitiers, France
| | - R. Gressin
- university hospital, nantes, France; university hospital, rennes, France; hospital, bobigny, France; university hospital, besancon, France; university hospital, grenoble, France; georges pompidou european hospital, paris, France; university hospital, clermont-ferrand, France; hospital, le mans, France; university hospital, montpellier, France; university hospital, poitiers, France
| | - C. Le Maignan
- university hospital, nantes, France; university hospital, rennes, France; hospital, bobigny, France; university hospital, besancon, France; university hospital, grenoble, France; georges pompidou european hospital, paris, France; university hospital, clermont-ferrand, France; hospital, le mans, France; university hospital, montpellier, France; university hospital, poitiers, France
| | - O. Tournilhac
- university hospital, nantes, France; university hospital, rennes, France; hospital, bobigny, France; university hospital, besancon, France; university hospital, grenoble, France; georges pompidou european hospital, paris, France; university hospital, clermont-ferrand, France; hospital, le mans, France; university hospital, montpellier, France; university hospital, poitiers, France
| | - J. Dugay
- university hospital, nantes, France; university hospital, rennes, France; hospital, bobigny, France; university hospital, besancon, France; university hospital, grenoble, France; georges pompidou european hospital, paris, France; university hospital, clermont-ferrand, France; hospital, le mans, France; university hospital, montpellier, France; university hospital, poitiers, France
| | - E. Legouffe
- university hospital, nantes, France; university hospital, rennes, France; hospital, bobigny, France; university hospital, besancon, France; university hospital, grenoble, France; georges pompidou european hospital, paris, France; university hospital, clermont-ferrand, France; hospital, le mans, France; university hospital, montpellier, France; university hospital, poitiers, France
| | - V. Delwail
- university hospital, nantes, France; university hospital, rennes, France; hospital, bobigny, France; university hospital, besancon, France; university hospital, grenoble, France; georges pompidou european hospital, paris, France; university hospital, clermont-ferrand, France; hospital, le mans, France; university hospital, montpellier, France; university hospital, poitiers, France
| |
Collapse
|
43
|
Leblond V, Tournilhac O, Morel P. Waldenstr�m?s macroglobulinemia: prognostic factors and recent therapeutic advances. Clin Exp Med 2004; 3:187-98. [PMID: 15103509 DOI: 10.1007/s10238-004-0025-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2003] [Revised: 08/04/2003] [Indexed: 10/26/2022]
Abstract
Waldenström's macroglobulinemia is a rare B cell malignancy. All prognostic studies have identified the adverse prognostic effect of advanced age and low hemoglobin level for survival, whereas the prognostic value of a high level of monoclonal component remains controversial. Response to treatment is probably a favorable prognostic factor for overall survival. Conventional treatment is based on alkylating agents, and especially chlorambucil. Purine analogues, used initially for salvage treatment, are increasingly employed as front-line therapy. Purine analogues have not been compared with alkylating agents as first-line therapy in randomized trials, and it is unclear whether purine analogues extend survival. An anti-CD20 monoclonal antibody has given a response rate in about 30% of patients. Autologous and allogeneic stem cell transplantation may be considered for patients with refractory or relapsing disease.
Collapse
Affiliation(s)
- V Leblond
- Service d'Hématologie, Hopital Pitié-Salpêtrière, 47 boulevard de l'Hôpital, 75013 Paris, France.
| | | | | |
Collapse
|
44
|
Mohty M, Jacot W, Faucher C, Bay JO, Zandotti C, Collet L, Choufi B, Bilger K, Tournilhac O, Vey N, Stoppa AM, Coso D, Gastaut JA, Viens P, Maraninchi D, Olive D, Blaise D. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003; 17:2168-77. [PMID: 12931226 DOI: 10.1038/sj.leu.2403105] [Citation(s) in RCA: 89] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
In the setting of reduced-intensity conditioning (RIC) regimens for allogeneic stem cell transplantation (allo-SCT), the epidemiology of transplant-related infections is still poorly defined. In 101 high-risk patients who received an HLA-identical sibling allo-SCT after RIC, including fludarabine, busulfan and antithymocyte globulin (ATG), we report during the first 6 months a cumulative incidence of positive CMV antigenemia of 42% (95% CI 32-52%), developing at a median of 37 (range 7-116) days without evidence of CMV disease (median follow-up, 434 days). The cumulative incidence of bacteremia was 25% (95% CI 17-33%), occurring at a median of 67 (range 7-172) days, while patients had recovered a full neutrophil count. In all, 65% of the bacteremia (95% CI 49-81%) were gram negative. The cumulative incidence of fungal infections was 8% (95% CI 3-13%), with a median onset of 89 (range 7-170) days. In multivariate analysis, stem cell source (bone marrow; P=0.0002) was significantly associated with the risk of positive CMV antigenemia, while higher doses of prednisone (>2 mg/kg) represented the major risk factor for bacteremia (P=0.0001). Infectious-related mortality was 5% (95% CI 1-9%), with aspergillosis being the principal cause. Collectively, these results suggest that prospective efforts are warranted to develop optimal antimicrobial preventive strategies after RIC allo-SCT.
Collapse
Affiliation(s)
- M Mohty
- Unité de Transplantation et de Thérapie Cellulaire, Institut Paoli-Calmettes, Marseille, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Beytout J, Tournilhac O, Laurichesse H. [Asplenia and hyposplenism]. Presse Med 2003; 32:S5-9. [PMID: 14631637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/27/2023] Open
Abstract
FROM ASPLENIA TO SEVERE INFECTION: The most serious consequence of asplenia due to absence of the spleen, its resection or its functional failure is the risk of severe infection. RAPIDLY PROGRESSIVE SEPTICEMIA: It is estimated that the risk of death due to septicemia is 200 times higher in splectomized patients than in patients with a spleen. Death occurs within several days or even hours in most of the patients due to overwhelming post-splenectomy infection (OPSI). The bacteria causing OPSI are predominantly pneumococci (50-80% of identified infections) as well as meningococci, Haemophilus sp, and other capsulated bacteria. IMPORTANCE OF AGE: The risk of infection is even greater if asplenia began early in life, either because of rapidly progressive congenital hemotological disease or splenectomy during infancy or early childhood. According to Holdsworth, infectious morbidity in subjects splenectomized before the age of 16 years is 4.4%, mortality reaches 2.2%. In adults, morbidity is 0.9% and mortality 0.8%. PREVENTION OF RECURRENCE: Furthermore, in an asplenic subject or in a patient with a chronic disease threatening the spleen, the development of infectious episodes is an expression of evolving immunodepression, calling for preventive measures against recurrence. Anti-pneumococcal vaccination and antibiotic prophylaxis using penicillin V considerably reduces the incidence of pneumococcal infection in splenectomized subjects.
Collapse
Affiliation(s)
- J Beytout
- Service des maladies infectieuses, Hôtel-Dieu, CHU de Clermont-Ferrand (63)
| | | | | |
Collapse
|
46
|
Beytout J, Tournilhac O, Laurichesse H. [Antibiotic prophylaxis in splenectomized adults]. Presse Med 2003; 32:S17-9. [PMID: 14631641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/27/2023] Open
Abstract
SIGNIFICANT INCIDENCE OF SPLENECTOMY: Asplenism concerns a significant number of subjects: in France 6,000 to 9,000 patients undergo splenectomy annually. More than half of these patients are adults. NECESSARY PREVENTION An asplenic adult is exposed to serious infections, predominantly caused by pneumococci but also by other encapsulated bacteria. Antibiotic prophylaxis is necessary and must be included in the overall management scheme in patients undergoing planned splenectomy. IN CLINICAL PRACTICE In France the official recommendation for antibiotic prophylaxis in the asplenic patient is Oracilline (Penicilline V) administered continuously for at least 2 years following splenectomy in adults and for at least 5 years following splenectomy in children. This prophylactic measure must be included in an overall program designed to prevent infections in asplenic patients.
Collapse
Affiliation(s)
- J Beytout
- Service des maladies infectieuses, Hôtel-Dieu, CHU de Clermont-Ferrand (63)
| | | | | |
Collapse
|
47
|
Tournilhac O, Leblond V, Tabrizi R, Gressin R, Senecal D, Milpied N, Cazin B, Divine M, Dreyfus B, Cahn JY, Pignon B, Desablens B, Perrier JF, Bay JO, Travade P. Transplantation in Waldenstrom's macroglobulinemia--the French experience. Semin Oncol 2003; 30:291-6. [PMID: 12720155 DOI: 10.1053/sonc.2003.50048] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Published data on transplantation in Waldenstrom's macroglobulinemia (WM) are still limited. We present a retrospective multicentric study of 27 WM patients who underwent 19 autologous (median age, 54 years) and 10 allogeneic (median age, 46 years) transplantations. Median time between diagnosis and transplantation was 36 months; 66% of patients had received three or more treatment lines and 72 % had chemosensitive disease. High-dose therapy (HDT) and autologous transplantation induced a 95% response rate (RR), including 10 major responses. With a median follow-up of 18 months, 12 patients are alive at 10 to 81 months and eight are free of disease progression at 10 to 34 months. The toxic mortality rate (TRM) was 6%. Allogeneic transplantation was preceded by HDT in nine patients and by a nonmyeloablative regimen in one patient. The RR was 80%, including seven major responses. With a median follow-up of 20.5 months, six patients are alive and free of progression at 3 to 76 months. Four patients died, all from toxicity, resulting in a TRM of 40%. HDT followed by autologous transplantation is feasible in WM, even in heavily pretreated patients, with some prolonged responses but a high relapse rate. Conversely, allogeneic transplantation is more toxic, but likely induces a graft-versus-WM effect and may, for some patients, result in long-term disease control.
Collapse
|
48
|
Boniol C, Tournilhac O, Kuder P, Guyon M, Dastugue B, Motta C, Sapin V. [Monoclonal IgM interference with immunoturbidimetric determination of transferrin]. Ann Biol Clin (Paris) 2002; 60:481-4. [PMID: 12147455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
Affiliation(s)
- C Boniol
- Laboratoire de biochimie, Hôtel-Dieu, CHU, boulevard Léon-Malfreyt, 63000 Clermont-Ferrand
| | | | | | | | | | | | | |
Collapse
|
49
|
Bay JO, Fleury J, Choufi B, Tournilhac O, Vincent C, Bailly C, Dauplat J, Viens P, Faucher C, Blaise D. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant 2002; 30:95-102. [PMID: 12132048 DOI: 10.1038/sj.bmt.1703609] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2001] [Accepted: 03/14/2002] [Indexed: 01/15/2023]
Abstract
Allogeneic hematopoietic stem cell transplantation is often used to treat hematologic malignancies. The efficacy of this procedure is due to both myeloablative conditioning and graft-versus-leukemia (GVL). However, the disadvantages of allogeneic transplantation include graft-versus-host disease (GVHD), relapse from the original tumor, and patient susceptibility to opportunistic infections. Lately, allogeneic transplantation has been developed to treat solid tumors, with the expectation that graft-versus-tumor (GVT), like GVL, will have a significant anti-tumor effect. This effect has been demonstrated in renal carcinomas, and with less evidence in breast cancers. Five patients with malignant ovarian tumors resistant to chemotherapy underwent allogeneic transplantation, four from bone marrow, and one from peripheral blood stem cells. All donors were HLA-identical siblings. One patient received a myeloablative conditioning regimen, while the other four received a non-myeloablative regimen. Two patients received donor lymphocyte infusions (DLI). Four of the patients presented with acute or chronic GVHD associated with tumor regression of at least 50%. These tumor regressions were measured by CA-125 levels and CT scans. The fifth patient died of rapid progression just after transplantation. Of the four transplantation survivors, three received a non-myeloablative regimen which did not seem to reduce treatment effectiveness. While it did reduce toxicity, one of these patients died of GVHD after 127 days. DLI was administered to two patients. These infusions seemed to promote GVHD which was able to control disease progression for one patient and had no apparent effect on the other. Allograft of hematopoietic stem cells might be of interest in ovarian cancer. The results in one patient also suggest that DLI may be an effective immunotherapy, although doses and timing need to be determined. The number of cases presented is small, however, and clinical experience on a larger scale will be required to determine the real clinical efficacy of graft versus cancerous ovarian cells.
Collapse
Affiliation(s)
- J-O Bay
- Unité de Transplantation Médullaire, Centre Jean Perrin, Centre de Lutte Contre le Cancer, 58 rue Montalembert, BP 392, 63011 Clermont-Ferrand cedex 1, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Leotard S, Chastang C, Travade P, Jaudon MC, Tournilhac O, Baudet S, Merle-Beral H. Prognostic relevance of a scoring system based on clinical and biological parameters in early chronic lymphocytic leukemia. Hematol J 2002; 1:301-6. [PMID: 11920207 DOI: 10.1038/sj.thj.6200055] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
INTRODUCTION Among patients with indolent form of B-cell chronic lymphocytic leukemia, some of them will progress into more advanced stages. To better define this subpopulation of patients, we attempted to define some parameters capable of predicting a pejorative clinical outcome. MATERIALS AND METHODS Eighty-eight previously untreated patients with B-cell chronic lymphocytic leukemia in Binet stage A were analysed to study the prognostic value of simple serological variables: soluble CD23 (sCD23), beta2 microglobulin (beta2m), lactate-dehydrogenase activities and albumin level. Results were compared to other conventional clinical and biological parameters by univariate and multivariate statistical analysis. RESULTS Our data show that: (1) among those studied, sCD23 >50 u/ml was the only serological significant parameter clearly correlated with disease progression and (2) stage A" patients (hemoglobin level between 100 and 120 g/l and/or lymphocytosis >30.10(9)/l), axillary lymph nodes and hypogammaglobulinemia were found to be other variables associated with a pejorative outcome. These four variables enabled the establishment of a scoring system, capable of predicting disease progression since 66% of the patients with a score < or =2 are going to evolve into advanced stages vs 12% with a score <2. Furthermore, the time to progression is shortened when the score is increasing. CONCLUSION Our findings show the prognostic relevance of a scoring system including sCD23 level. This score could be taken into account in the treatment strategy of B-cell chronic lymphocytic leukemia.
Collapse
MESH Headings
- Adult
- Agammaglobulinemia/etiology
- Aged
- Analysis of Variance
- Disease Progression
- Female
- Follow-Up Studies
- Humans
- L-Lactate Dehydrogenase/blood
- Leukemia, Lymphocytic, Chronic, B-Cell/blood
- Leukemia, Lymphocytic, Chronic, B-Cell/classification
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Liver/pathology
- Lymph Nodes/pathology
- Lymphocyte Count
- Male
- Middle Aged
- Neoplasm Staging
- Predictive Value of Tests
- Receptors, IgE/analysis
- Retrospective Studies
- Serum Albumin/analysis
- Severity of Illness Index
- Spleen/pathology
- beta 2-Microglobulin/analysis
Collapse
Affiliation(s)
- S Leotard
- Service d'Hématologie Biologique, Pitié-Salpêtrière Hospital, 47 Boulevard de l'Hôpital, 75013 Paris, France
| | | | | | | | | | | | | |
Collapse
|